ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,917.11
0.00%
Dow Jones
43,408.47
0.32%
US Dollar vs MXN
20.3354
0.26%
Brent Oil
73.42
0.80%
Bitcoin
96,967.29
2.76%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. USOTC

  6. Elite Pharmaceuticals Inc (QB) (ELTP) Cotización

Elite Pharmaceuticals Inc (QB)

Elite Pharmaceuticals Inc (QB) (ELTP)

USOTC
0.6635
-0.0115
(-1.70%)
Cerrado 21 Noviembre 3:00PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
0.6635
Postura de Compra
0.651
Postura de Venta
0.667
Volume Operado de la Acción
1,534,474
0.627 Rango del Día 0.70
0.1213 Rango de 52 semanas 0.7598
Capitalización de Mercado [m]
708.799M
Precio Anterior
0.675
Precio de Apertura
0.685
Hora
8323
@
0.6635
Última hora de negociación
Volumen financiero
US$ 1,027,575
Precio Promedio Ponderado
0.669659
Volumen promedio (3 m)
3,659,362
Acciones en circulación
1,068,273,108
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
35.11
Beneficio por acción (BPA)
0.02
turnover
56.63M
Beneficio neto
20.11M

Acerca de Elite Pharmaceuticals Inc (QB)

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products which have been licensed to Lannett Company, Prasco, LLC, Epic Pharma... Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products which have been licensed to Lannett Company, Prasco, LLC, Epic Pharma, LLC, and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.elitepharma.com
Sede
Carson City, Nevada, USA
Fundado
-
Elite Pharmaceuticals Inc (QB) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker ELTP. The last closing price for Elite Pharmaceuticals (QB) was US$0.68. Over the last year, Elite Pharmaceuticals (QB) shares have traded in a share price range of US$ 0.1213 to US$ 0.7598.

Elite Pharmaceuticals (QB) currently has 1,068,273,108 shares in issue. The market capitalisation of Elite Pharmaceuticals (QB) is US$721.08 million. Elite Pharmaceuticals (QB) has a price to earnings ratio (PE ratio) of 35.11.

ELTP Últimas noticias

Más noticias

Form 8-K - Current report

18 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

14 Noviembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

14 Noviembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

28 Octubre 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

23 Octubre 2024
Edgar (US Regulatory)

ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition

ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition     Miami, FL – October 23, 2024 -- InvestorsHub NewsWire – EmergingGrowth.com, a leading...

23 Octubre 2024
InvestorsHub NewsWire

Form 8-K - Current report

10 Octubre 2024
Edgar (US Regulatory)

Form 8-K - Current report

27 Agosto 2024
Edgar (US Regulatory)

Form 8-K - Current report

14 Agosto 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

14 Agosto 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.093516.40350877190.570.720.4842269870.60786659CS
40.05599.200131665570.60760.720.432134661130.53164122CS
120.4045156.1776061780.2590.75980.245736593620.47222268CS
260.5145345.3020134230.1490.75980.14521340040.41387367CS
520.511335.0819672130.15250.75980.121316410750.32796916CS
1560.62771753.351955310.03580.75980.0239613630.2134645CS
2600.575649.7175141240.08850.75980.0239661280.15381409CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
EGRNFChina Evergrande Group (CE)
US$ 0.0102
(1,019,900.00%)
900
WRCDFWirecard AG (CE)
US$ 0.01
(999,900.00%)
350
CCTLCoin Citadel (PK)
US$ 0.0002
(19,900.00%)
1.28M
RDVARDVA Inc (CE)
US$ 0.0002
(19,900.00%)
10k
AGRDFMinnova Corporation (PK)
US$ 0.0101
(10,000.00%)
10k
ISUNQiSun Inc (CE)
US$ 0.000001
(-99.86%)
12.5k
YAYOYayYo Inc (CE)
US$ 0.000001
(-99.80%)
44.61k
GBCHFMetaverse Capital Corporation (CE)
US$ 0.000001
(-99.00%)
200
NTRRNeutra Corporation (CE)
US$ 0.000001
(-99.00%)
40k
BTTXBetter Therapeutics Inc (CE)
US$ 0.000001
(-99.00%)
60.2k
THBDThird Bench Inc (PK)
US$ 0.0001
(0.00%)
183.32M
RDARRaadr Inc (PK)
US$ 0.0006
(-25.00%)
131.72M
BDPTBioadaptives Inc (PK)
US$ 0.0001
(-50.00%)
121.82M
GRLFGreen Leaf Innovations Inc (PK)
US$ 0.0001
(0.00%)
111.8M
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0.003
(-14.29%)
97.54M

ELTP Discussion

Ver más
The ELTP King The ELTP King 8 minutos hace
Nasrat promised "at least" two filings by the end of 2024 which means two positive BE studies.

Both BE studies failed.

Now he did say "at least" two filing so maybe the third BE study will actually pass?

Sure would be nice to get another BE or two up to the plate as it can take over a year to get a newly approved BE to market.
👍️0
The ELTP King The ELTP King 10 minutos hace
So not only is Nasrat hurting Elite with his Mikah nonsense, he's hurting Elite with his warrant nonsense as well.

The reason warrants are recorded as a liability because it shows the fair value loss the company is realizing during the fiscal period by issuing shares at current share price vs the warrant strike price. It's the amount Elite is out of the money on as a gift to Nasrat.
👍️0
The ELTP King The ELTP King 12 minutos hace
Do you have a learning disability?

They can't FREAKING buy ELTP because their brokerages don't allow it.

Tell everyone you know to tell 10 people to buy $100+ we can start a new MOASS like GME
👍️0
The ELTP King The ELTP King 13 minutos hace
NOBODY wants stock of another company when Elite gets purchased in 2026 or 2027.

100% CASH.

I invested in Elite, not some other DOUCHEBAG company.

Love it stock and dividend. Love it. Love it love it.
👍️0
The ELTP King The ELTP King 15 minutos hace
You JUST proved my point and other people's points that are of my same mindset.

OF COURSE Nasrat isn't selling anytime soon for the VERY reason you mentioned!

LMAO!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

The point being the longer a potential buyer waits, revenues increase probability increases our price gets higher!!!!!!!
👍️0
The ELTP King The ELTP King 19 minutos hace
LMAO.

He can't buy the full 7.5 million shares until January 2026 - OVER a year away.

Like I said, Elite ain't being sold ANY time soon.

It was so obvious and my thoughts are that it will happen after Doug buys those 7 million shares at .03 that are available to him in January.
👍️0
The ELTP King The ELTP King 25 minutos hace
You're so gullible.

Nasrat's LITERALLY been saying that EVERY SINGLE YEAR since 2014 -- 10 FREAKING YEARS!

In 2017 he PROMISED shareholders that we'd be on the Nasdaq by 2019 AND we'd be in Dollarland by 2019.

“We are in a position that is very attractive for a pharmaceutical company with consistent profits, steady growth and low debt. And we are in a great position, a strong position for merger and acquisition if the price is right or a move up to NASDAQ.”

Read carefully and you will see his priority is the acquisition, not Nasdaq. Don’t be surprised if we have multiple bidders. That and the fact that Carter mentioned be evaluated. A tender offer is based on present and FUTURE revenue.
👍️0
The ELTP King The ELTP King 27 minutos hace
Charles Schwab.

Fidelity Investments is the best brokerage service by a wide margin.
👍️0
The ELTP King The ELTP King 29 minutos hace
Nasrat said he's going to conduct a reverse split at the same time of a major news event when uplisting to the Nasdaq in order to avoid the stock tanking right afterwards (because he knows most OTC investors are IDIOTS and think that reverse splits are always bad).

You think Elite will conduct a 10 to 1 reverse split on the launch of Vyvanse since that will be a major news event?

It would perfectly align with the start of the new year since Vyvanse will launch by January 1.

The ONLY problem I see with this scenario is MIKAH is still on the balance sheet and Nasrat will have address this in the February conference call ASSUMING he holds live conference calls again (wouldn't they have to be live since we'd now be on the Nasdaq?)

PS: We could also MERGE with another company to get on the Nasdaq to avoid a reverse split.

Let's see an actual share price target. Maybe in 2025 if we uplist to NASDAQ.
👍️0
kayak_wench kayak_wench 3 horas hace
The last BE study PR we got was on Aug 28, 2023 for Vyvanse (during Q2 2024).
From Q3 2024 (starting at Q3 because I can't know if any of Q2 was for Vyvanse studies) forward Elite has spent a total of $7.2M on research and development. Sure would be nice to get another BE or two up to the plate as it can take over a year to get a newly approved BE to market. The first half of calendar year 2025 will be on growing markets of new products, but I expect we will be topping out by end of summer (with that period being reported in Nov 2025). Of course Purdue could give up sometime in the year and that would definitely give us more fuel to continue growth.

Research and development expenses since Vyvanse's successful BE
Q3 2024 1.4M
Q4 2024 6.9M - (1.1M+2.6M+1.4M) = 1.8M
Q1 2025 2.1M
Q2 2025 1.9M
👍️0
kayak_wench kayak_wench 4 horas hace
I don't agree that the $0.60 is the value the market gave t use for our current drug line. I believe at $0.60 the market was starting to price in the Vyvance because we didn't hit that until Nov 18th during the conference call. The price was consolidating to the low 0.51 to 0.52 range (ringing up and down to get there of course) until a few minutes into the conference call when it became evident that the Carter and Nasrat were in good moods. It was during that call we learned everything was still going fine. So you are missing a dime off the impact of Vyvance....and that is the impact so far. Remember the mid-Aug call when Nasrat told us of the continuous wave of new products. The market didn't really price that in for a couple of weeks.
👍️0
HGilS HGilS 5 horas hace
Me 2.
👍️0
Destiny Defined Destiny Defined 6 horas hace
I love the guy, and think he's done a great job. His intelligence, and sense of humor are top tier. The MEGA stuff had me dying. 😆
👍️ 2
HGilS HGilS 6 horas hace
You bet he is.
👍️0
NASDAQ2020 NASDAQ2020 6 horas hace
Is IB still on the MB ?
👍️0
Destiny Defined Destiny Defined 6 horas hace
I was poking fun of the stupid bashers calling him that...tied in with a play on, "Can you smell what the Rock is cooking?" As in...Nasrat has a plan and is executing it very well. If anyone is too daft to either already have or decide to now take a seat at his table, their loss. I've been a long since 2009, dude. Check out my posting history. I knew N2k personally. So....
👍️ 3
HGilS HGilS 6 horas hace
I can’t stand people calling the ceo the rat. Destiny is ib_
👍️0
HGilS HGilS 6 horas hace
No we don’t. what are you cooking destiny defined?
👍️0
NASDAQ2020 NASDAQ2020 6 horas hace
Correction:
1/2 ownership of the profit split of Adderalls ($2B market) = $0.60

Full ownership of Vyvance ($4.3B) = $0.06 more

Todays price $$0.66

Forward lookin’ Market was well aware that Vyvance was definitely going to get approval first time around due to Nasrats awesome track record with ANDA approvals.
👍️0
Destiny Defined Destiny Defined 6 horas hace
Seed has been planted. Harvest will be here in due time. Our little farma gonna be growing all sorts of greenery for us to feast upon. My seat at the table has already been secured. Can you smell what the "Rat" is cooking? Lol....
👍 1
HGilS HGilS 6 horas hace
2 big catalysts by year end. This should fix it.
🎓️ 1 👍️ 1
NASDAQ2020 NASDAQ2020 6 horas hace
Vyvance in extreme shortage has the potential to take a more significant market share since its API supplier is different than all the other competitors .
10-15-20% potentially of a $4.3 B market.
Today’s forward looking Value factored in = $0.06 since approval.
👍️ 2
jour_trader jour_trader 7 horas hace
It's half ownership of the profit split, not the mfg revenue. 
🤪 1
NASDAQ2020 NASDAQ2020 7 horas hace
1/2 ownership of Adderalls ($2B market) = $0.60

Full ownership of Vyvance ($4.3B) = $0.06 more

Todays price $$0.66
👍️0
Destiny Defined Destiny Defined 7 horas hace
C'mon, man. Reality ain't no fun. 🤪
👍️0
jour_trader jour_trader 7 horas hace
Companies present non-GAAP metrics all of the time. They have a separate deck and this is what they walk through - results, comparisons, key metrics, forecast, etc. 

You don't exclude it from GAAP reporting to SEC, but you most certainly can report it in a PR and during cc when reviewing financials.
👍️0
jour_trader jour_trader 7 horas hace
How could they buy 500M shares without spiking the share price?  I don't think that is realistic. 
👍️0
VortexAstronaut781 VortexAstronaut781 8 horas hace
Not just reddit but some folks here too. Yes I would love to see this stock go higher too, doesn't mean every negative price action is result of so called manipulation....
👍 1
DividendGamer DividendGamer 8 horas hace
Really hate to see all these claims of manipulation on reddit about Wall Street boogeymen "manipulators", so sick of all this GME MOASS nonsense on every stock forum like reddit etc. Thinner markets have lower volume and broader swings, it is as simple as that. OTC are pretty much as thin as they get aside from private share groups. I have stock in OTC companies that I can easily see each of my trades when less than 1k trade a day. Some of them are so thinly traded the ticker doesn't even make the correct tape updates because of the minimum update thresholds. There is no conspiracy, just big versus small markets.
👍️ 3
Trend-Setter Trend-Setter 8 horas hace
A poster on YMB is impersonating Pharma Sleuth. If you check the posting history, you'll figure out who that person is.
👍️ 2 🙄 1 🤔 1
aBeezlee aBeezlee 8 horas hace
I get the impression this will spike by EOM. Waiting for my transfer to complete, hopefully by Friday.
👍️ 1 🙄 1
Son of Tangerine Son of Tangerine 9 horas hace
Clearly AI written too. Ever wonder how much money they get on clicks from that stuff? Is it like automated mad libs? So much AI content out there right now. How long you think it takes to generate each article?

I think they did do one that wasn't AI.
👍 3 🙄 1
jour_trader jour_trader 9 horas hace
Yes, lol. Zack's published quite the number for the financially illiterate.
🎓️ 1 👍️ 1
Son of Tangerine Son of Tangerine 9 horas hace
Dear lord, please don't let the stock price go up so the P&L looks better when we calculate the increasing derivative value due to the stock going up and the company having massive growth?
👍️ 4 😂 5
Son of Tangerine Son of Tangerine 9 horas hace
For the completely ignorant ?
👍️ 2
Son of Tangerine Son of Tangerine 9 horas hace
If you sold and are trying to buy your shares back, just say it. You have been spouting nonsense since the stock was .03. Anyone that listened ..well...shouldn't have and shouldn't ever.
👍️ 8 💯 4
jour_trader jour_trader 9 horas hace
It's all optics
👍️0
Son of Tangerine Son of Tangerine 9 horas hace
Huh? You give a crap about derivatives because the stock went up? You like having bigger P&L when the stock goes down? No one gives a crap about derivatives in determining the value of a company.
👍️ 4
csuck555 csuck555 9 horas hace
Everyone here should be putting their entire net worth into this at these prices! 
Utter embarrassment that we're not over $1.00 already.  
🎓️ 1 👍️ 4 💯 3
NASDAQ2020 NASDAQ2020 10 horas hace
What was priced in at $0.75 ?

Probably was high so to take out more stop losses
TIA
👧 1 👶 1
NASDAQ2020 NASDAQ2020 10 horas hace
I think he left at $0.15.
👍️0
jour_trader jour_trader 10 horas hace
From a P&L standpoint, we may have a bigger loss next Q due to warrants. Share price has surged since end of last fiscal Q. Even with a large increase in rev, I don't think this will solve for the accounting of the warrants. This will be a noose around our neck from P&L optics standpoint. 

The reason warrants are recorded as a liability because it shows the fair value loss the company is realizing during the fiscal period by issuing shares at current share price vs the warrant strike price.  It's the amount Elite is out of the money  
on as a gift to Nasrat.
👍️0
The ELTP King The ELTP King 10 horas hace
Market is forward looking.

Vyvanse is priced in and so are all the upcoming ANDA launches.

Need a positive BE study if we want the PPS to rise more.

Nasrat said AT LEAST two filings by the end of 2024. (HE LIED. WE WON'T RECEIVE ANY)
❓️ 1
The ELTP King The ELTP King 10 horas hace
Do you know how many people submitted questions and/or threatened Nasrat with legal action about Mikah this last CC?

Wonder if WeeZuhl raised HELL about this?

I think the issue is MIKAH
👍️0
VortexAstronaut781 VortexAstronaut781 10 horas hace
This is way less pullback than I anticipated, hopefully we get whales buy in and form new support over next week
👍️ 3
BoyWidaDreamOr2 BoyWidaDreamOr2 11 horas hace
Jammy!!! Why do you do this???

P.S. please remove my 1 post/day limit thxxx
👍️0
IB_ IB_ 11 horas hace
Almost ........... $0.70 was close !!!!!!!!!!!!!!!!!!!!!!!!!

IB_🤴
👍️0
Cake Eater Cake Eater 12 horas hace
I'll call Joaquin Duato, the current Chairman and Chief Executive Officer of Johnson & Johnson and get things rolling.
He may "LOVE IT" also 🤷‍♂️😂
👍 1 🤣 1
Cake Eater Cake Eater 12 horas hace
Next you will be using this RD line:

"I was so poor, my rich aunt died; in the will, I owed her $20."
👍️0
sharkey1 sharkey1 12 horas hace
Lets remember how to use the force as we live our daily lives



you can do this
👍 1

Su Consulta Reciente

USOTC
ELTP
Elite Pharmaceuticals (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados